Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Pioltelli Maria Luisa; Pungolino Ester; Dadda Mariella; Elena Chiara; Borin Lorenza Maria; Perego Alessandra; Iurlo Alessandra; Trojani Alessandra; Turrini Mauro; Caramella Marianna; Spedini Pierangelo; Malato Simona; Spina Francesco; Artale Salvatore; Carraro Mariacristina; Orofino Nicola; Anghilieri Michela; Farina Mirko; Latargia Maria Luisa; Rossi Giuseppe; Morra Enrica; Cairoli Roberto

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

【24h】

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

机译：将伊替尼 - 后尼洛替尼治疗结合在慢性相慢性骨髓白血病的第一线疗法中。在哲学24个月的后续行动时从哲学研究更新

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共4页
作者
Pioltelli Maria Luisa; Pungolino Ester; Dadda Mariella; Elena Chiara; Borin Lorenza Maria; Perego Alessandra; Iurlo Alessandra; Trojani Alessandra; Turrini Mauro; Caramella Marianna; Spedini Pierangelo; Malato Simona; Spina Francesco; Artale Salvatore; Carraro Mariacristina; Orofino Nicola; Anghilieri Michela; Farina Mirko; Latargia Maria Luisa; Rossi Giuseppe; Morra Enrica; Cairoli Roberto;
展开▼
作者单位

ASST Grande Osped Metropolitano Niguarda Dept Hematol Milan Italy;

ASST Grande Osped Metropolitano Niguarda Dept Hematol Milan Italy;

ASST Spedali Civili Brescia Dept Hematol Brescia Italy;

Fdn IRCCS Policlin San Matteo Dept Hematol Oncol Pavia Italy;

San Gerardo Hosp Dept Hematol Monza Italy;

Desio Hosp Internal Med Hematol Desio Italy;

Fdn IRCCS Ca Granda Osped Maggiore Policlin Hematol Div Milan Italy;

ASST Grande Osped Metropolitano Niguarda Dept Hematol Milan Italy;

Valduce Hosp Dept Internal Med Como Italy;

ASST Grande Osped Metropolitano Niguarda Dept Hematol Milan Italy;

ASST Cremona Cremona Italy;

San Raffaele Sci Unit Hematol &

Bone Marrow Transplantat Unit Milan Italy;

Fdn IRCCS Ist Tumori Div Hematol Milan Italy;

ASST Valle Olona St Antonio Abate Gallarate Italy;

L Sacco Univ Hosp Hematol &

Transfus Med Milan Italy;

Univ Milan Fdn IRCCS Ca Granda Osped Maggiore Policlin Hematol Unit Milan Italy;

ASST Lecco Lecce Italy;

ASST Spedali Civili Brescia Dept Hematol Brescia Italy;

ASST Valle Olona Osped Circolo Busto Arsizio Italy;

ASST Spedali Civili Brescia Dept Hematol Brescia Italy;

ASST Grande Osped Metropolitano Niguarda Lombardy Hematol Network Milan Italy;

ASST Grande Osped Metropolitano Niguarda Dept Hematol Milan Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up [J] . Pioltelli Maria Luisa, Pungolino Ester, Dadda Mariella, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：将伊替尼 - 后尼洛替尼治疗结合在慢性相慢性骨髓白血病的第一线疗法中。在哲学24个月的后续行动时从哲学研究更新
2. Final Analysis of the Efficacy and Safety of Omacetaxine Mepesuccinate in Patients With Chronic- or Accelerated-Phase Chronic Myeloid Leukemia: Results With 24 Months of Follow-Up [J] . Cortes Jorge E., Kantarjian Hagop M., Rea Delphine, Cancer: A Journal of the American Cancer Society . 2015,第10期

机译：盐酸奥美西他滨对慢性或加速期慢性粒细胞白血病患者的疗效和安全性的最终分析：随访24个月的结果
3. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. [J] . Tim H Brümmendorf, Jorge E Cortes, Cármino Antonio de Souza, British Journal of Haematology . 2015,第1期

机译：博舒替尼与伊马替尼治疗新诊断的慢性期慢性粒细胞白血病：BELA试验24个月的随访结果。
4. Combining pharmacological therapy and vaccination in Chronic Myeloid Leukemia via model predictive control [C] . Laurino, Marco, Stano, Maurizio, Betta, Monica, Annual Conference of Japanese Society for Medical and Biological Engineering;Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2013

机译：通过模型预测控制将药理学疗法和疫苗接种相结合用于慢性粒细胞白血病
5. Antisense and drug-resistance gene therapy in a mouse model of chronic myeloid leukemia. [D] . Sweeney, Colin Lee. 2003

机译：慢性粒细胞白血病小鼠模型中的反义和耐药基因治疗。
6. Final Analysis of Efficacy and Safety of Omacetaxine Mepesuccinate in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML): 24-Month Minimum Follow-Up Results [O] . Jorge Cortes, Hagop M. Kantarjian, Delphine Rea, -1

机译：盐酸奥马西汀甲磺酸琥珀酸酯对慢性期（CP）或加速期（AP）慢性粒细胞白血病（CML）患者的疗效和安全性的最终分析：24个月最低随访结果
7. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia : results from the 24-month follow-up of the BELA trial [O] . Brümmendorf, Tim Henrik, Cortes, Jorge E., de Souza, Cármino Antonio, 2015

机译：博舒替尼与伊马替尼治疗新诊断的慢性期慢性粒细胞白血病：BELA试验24个月的随访结果

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

著录项

相似文献

相关主题

期刊订阅